HOOKIPA Pharma Inc. (HOOK)

Market Cap	56.15M
Revenue (ttm)	53.55M
Net Income (ttm)	-47.52M
Shares Out	96.55M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	419,169
Open	0.627
Previous Close	0.628
Day's Range	0.576 - 0.630
52-Week Range	0.410 - 1.130
Beta	0.75
Analysts	Strong Buy
Price Target	5.00 (+759.7%)
Earnings Date	Aug 8, 2024

About HOOK

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 18, 2019
• Employees: 151
• Stock Exchange: NASDAQ
• Ticker Symbol: HOOK

Financial Performance

In 2023, HOOKIPA Pharma's revenue was $20.13 million, an increase of 41.27% compared to the previous year's $14.25 million. Losses were -$81.58 million, 25.7% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for HOOK stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 759.70% from the latest price.

Price Target

$5.0

(759.70% upside)

Analyst Consensus: Strong Buy